CYP4Z1 and breast cancer: Further studies are therefore required to delineate the role CYP4Z1 plays in breast cancer, specifically identifying the metabolite responsible for inducing growth and angiogenesis, as well as how HET0016 is able to mitigate the effects of CYP4Z1 overexpression.